CERUS CORP (CERS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cerus Corporation on July 2, 2024, reporting events occurring on July 1, 2024. The filing pertains to corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive appointments and compensation arrangements.
Material Changes
The primary material change reported is the appointment of Dean Gregory to the Board of Directors, effective July 1, 2024. Mr. Gregory, formerly the President of Global Commercial Operations, Med Tech for Fresenius Kabi, will serve in the director class expiring at the 2027 annual meeting.
Compensation and Governance Details
- Cash Retainer: Mr. Gregory is entitled to an annual cash retainer of $45,000, paid quarterly and pro-rated for the first quarter of service.
- Initial Equity Grant: Upon election, Mr. Gregory received a Restricted Stock Unit (RSU) award for 60,000 shares of common stock. These units vest in three annual installments contingent on continued service.
- Annual Equity Grant: Future annual RSU grants are valued at $200,000, calculated based on the average daily closing sales price over the 30 trading days prior to the grant date. These vest in full on the later of the first anniversary of the grant or the day prior to the next annual meeting.
- Change in Control: All outstanding equity held by Mr. Gregory will fully vest immediately prior to a "change in control" event, subject to continuous service.
- Indemnification: Mr. Gregory will enter into the Company's standard indemnity agreement for directors and officers.
Investor Verification Checklist
- Verify the exact vesting schedule and cliff dates for the initial 60,000 RSU grant.
- Confirm the calculation methodology for the $200,000 annual RSU grant based on the 30-day average share price.
- Review the full text of the Amended and Restated Non-Employee Director Compensation Policy (to be filed in the Q2 2024 10-Q) for additional terms.
- Assess the impact of the new board member's background in Med Tech commercial operations on the Company's strategic direction.